ESSEX BIO-TECH (01061) Deemed Undervalued by Guoyuan International, Analyst Recommends Close Monitoring

Stock News03-26 11:26

Guoyuan International has released a research report stating that ESSEX BIO-TECH (01061) achieved a turnover of HKD 1.814 billion in 2025, an increase of 8.6% compared to 2024, primarily driven by sustained growth in its ophthalmology and surgical segments. Profit rose by 3.5% to HKD 318 million compared to the previous year. The product Beifushu has been successfully introduced to the Singapore National Eye Centre through Singapore's special access pathway. This milestone marks the product's first entry into a market outside China, laying the groundwork for future launches in Southeast Asia and global markets. The report indicates that the company's core business is growing steadily, providing strong cash flow. The Phase III clinical trial for the new product, bevacizumab, has met its primary clinical endpoints. This product has significant potential in both domestic and international markets. The successful future commercialization of this innovative drug is expected to drive the company's performance upward. The current static P/E ratio is only 6.5 times, suggesting the stock is undervalued, and investors are advised to actively monitor it.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157400728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157400728","market":"hk","top_or_hot":-1,"title":"ESSEX BIO-TECH (01061) Deemed Undervalued by Guoyuan International, Analyst Recommends Close Monitoring","media":"Stock News","content":"<p>Guoyuan International has released a research report stating that ESSEX BIO-TECH (01061) achieved a turnover of HKD 1.814 billion in 2025, an increase of 8.6% compared to 2024, primarily driven by sustained growth in its ophthalmology and surgical segments. Profit rose by 3.5% to HKD 318 million compared to the previous year. The product Beifushu has been successfully introduced to the Singapore National Eye Centre through Singapore's special access pathway. This milestone marks the product's first entry into a market outside China, laying the groundwork for future launches in Southeast Asia and global markets. The report indicates that the company's core business is growing steadily, providing strong cash flow. The Phase III clinical trial for the new product, bevacizumab, has met its primary clinical endpoints. This product has significant potential in both domestic and international markets. The successful future commercialization of this innovative drug is expected to drive the company's performance upward. The current static P/E ratio is only 6.5 times, suggesting the stock is undervalued, and investors are advised to actively monitor it.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSEX BIO-TECH (01061) Deemed Undervalued by Guoyuan International, Analyst Recommends Close Monitoring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSEX BIO-TECH (01061) Deemed Undervalued by Guoyuan International, Analyst Recommends Close Monitoring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-26 11:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Guoyuan International has released a research report stating that ESSEX BIO-TECH (01061) achieved a turnover of HKD 1.814 billion in 2025, an increase of 8.6% compared to 2024, primarily driven by sustained growth in its ophthalmology and surgical segments. Profit rose by 3.5% to HKD 318 million compared to the previous year. The product Beifushu has been successfully introduced to the Singapore National Eye Centre through Singapore's special access pathway. This milestone marks the product's first entry into a market outside China, laying the groundwork for future launches in Southeast Asia and global markets. The report indicates that the company's core business is growing steadily, providing strong cash flow. The Phase III clinical trial for the new product, bevacizumab, has met its primary clinical endpoints. This product has significant potential in both domestic and international markets. The successful future commercialization of this innovative drug is expected to drive the company's performance upward. The current static P/E ratio is only 6.5 times, suggesting the stock is undervalued, and investors are advised to actively monitor it.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1157400728","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157400728","pubTimestamp":1774495587,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Guoyuan International has released a research report stating that ESSEX BIO-TECH (01061) achieved a turnover of HKD 1.814 billion in 2025, an increase of 8.6% compared to 2024, primarily driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技","BK1161":"生物科技"},"translate_title":"亿胜生物(01061)被国元国际视为低估，分析师建议密切监察","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Guoyuan International has released a research report stating that ESSEX BIO-TECH (01061) achieved a turnover of HKD 1.814 billion in 2025, an increase of 8.6% compared to 2024, primarily driven by sustained growth in its ophthalmology and surgical segments. Profit rose by 3.5% to HKD 318 million compared to the previous year. The product Beifushu has been successfully introduced to the Singapore National Eye Centre through Singapore's special access pathway. This milestone marks the product's first entry into a market outside China, laying the groundwork for future launches in Southeast Asia and global markets. The report indicates that the company's core business is growing steadily, providing strong cash flow. The Phase III clinical trial for the new product, bevacizumab, has met its primary clinical endpoints. This product has significant potential in both domestic and international markets. The successful future commercialization of this innovative drug is expected to drive the company's performance upward. The current static P/E ratio is only 6.5 times, suggesting the stock is undervalued, and investors are advised to actively monitor it.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157400728","isCrawlerRequest":true}